• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity.原发性胰腺癌细胞的表观遗传重编程可逆转其体内致瘤性。
Oncogene. 2019 Aug;38(34):6226-6239. doi: 10.1038/s41388-019-0871-x. Epub 2019 Jul 15.
2
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.使用 5-氮杂胞苷进行表观遗传重编程可促进胰腺腺癌细胞的抗癌反应。
Cell Death Dis. 2018 May 1;9(5):468. doi: 10.1038/s41419-018-0487-z.
3
PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer.PRMT1 促进与胰腺癌获得性化疗耐药相关的表观遗传重编程。
Cell Rep. 2024 May 28;43(5):114176. doi: 10.1016/j.celrep.2024.114176. Epub 2024 Apr 30.
4
Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.靶向 PIN1 通过抑制肿瘤转移发挥强大的抗肿瘤活性在胰腺导管腺癌中。
Cancer Sci. 2019 Aug;110(8):2442-2455. doi: 10.1111/cas.14085. Epub 2019 Jun 25.
5
MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.miR-143-3p 通过靶向 KRAS 抑制胰腺导管腺癌的肿瘤发生。
Biomed Pharmacother. 2019 Nov;119:109424. doi: 10.1016/j.biopha.2019.109424. Epub 2019 Sep 12.
6
MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.MUC1-C 决定胰腺导管腺癌中的神经内分泌谱系特化。
Carcinogenesis. 2022 Feb 11;43(1):67-76. doi: 10.1093/carcin/bgab097.
7
MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.微小RNA-323-3p通过直接抑制SMAD2和SMAD3抑制胰腺导管腺癌的细胞侵袭和转移。
Oncotarget. 2016 Mar 22;7(12):14912-24. doi: 10.18632/oncotarget.7482.
8
Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.Setd2 缺失促进 Kras 诱导的胰腺发生过程中的腺泡到导管化生和上皮间质转化。
Gut. 2020 Apr;69(4):715-726. doi: 10.1136/gutjnl-2019-318362. Epub 2019 Jul 11.
9
Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.EZH2 通过诱导异染色质形成沉默人胰腺导管腺癌细胞中的 microRNA-218。
Gastroenterology. 2013 May;144(5):1086-1097.e9. doi: 10.1053/j.gastro.2013.01.058. Epub 2013 Feb 7.
10
An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.长链非编码 RNA PANDAR 的表达增加促进胰腺导管腺癌细胞增殖并抑制细胞凋亡。
Biomed Pharmacother. 2017 Nov;95:685-691. doi: 10.1016/j.biopha.2017.08.124. Epub 2017 Sep 7.

引用本文的文献

1
RAG1 and RAG2 non-core regions are implicated in leukemogenesis and off-target V(D)J recombination in BCR-ABL1-driven B-cell lineage lymphoblastic leukemia.RAG1 和 RAG2 的非核心区域与 BCR-ABL1 驱动的 B 细胞谱系淋巴母细胞白血病中的白血病发生和非靶点 V(D)J 重组有关。
Elife. 2024 Jul 26;12:RP91030. doi: 10.7554/eLife.91030.
2
The occurrence and development of induced pluripotent stem cells.诱导多能干细胞的发生与发展。
Front Genet. 2024 Apr 18;15:1389558. doi: 10.3389/fgene.2024.1389558. eCollection 2024.
3
Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells.仙台病毒在将基因导入人胰腺癌细胞方面表现强劲且稳定。
Heliyon. 2024 Feb 28;10(5):e27221. doi: 10.1016/j.heliyon.2024.e27221. eCollection 2024 Mar 15.
4
Reprogramming and multi-lineage transdifferentiation attenuate the tumorigenicity of colorectal cancer cells.重编程和多谱系转分化可减弱结直肠癌细胞的致瘤性。
J Biol Chem. 2024 Jan;300(1):105534. doi: 10.1016/j.jbc.2023.105534. Epub 2023 Dec 10.
5
Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors.诱导多能干细胞在恶性实体肿瘤中的应用。
Stem Cell Rev Rep. 2023 Nov;19(8):2557-2575. doi: 10.1007/s12015-023-10633-y. Epub 2023 Sep 27.
6
High OCT4 Expression Might Be Associated with an Aggressive Phenotype in Rectal Cancer.高OCT4表达可能与直肠癌的侵袭性表型相关。
Cancers (Basel). 2023 Jul 23;15(14):3740. doi: 10.3390/cancers15143740.
7
Dedifferentiation and reprogramming of committed cells in wound repair (Review).在伤口修复中,定向细胞的去分化和重编程(综述)。
Mol Med Rep. 2022 Dec;26(6). doi: 10.3892/mmr.2022.12886. Epub 2022 Nov 2.
8
Molecular Markers of Pancreatic Cancer: A 10-Year Retrospective Review of Molecular Advances.胰腺癌的分子标志物:分子进展的10年回顾性综述
Cureus. 2022 Sep 23;14(9):e29485. doi: 10.7759/cureus.29485. eCollection 2022 Sep.
9
Combined transgene immortalized urothelial cells capable of reprogramming and hepatic differentiation.能够重编程和肝分化的联合转基因永生化尿路上皮细胞。
Biochem Biophys Rep. 2022 Jul 16;31:101308. doi: 10.1016/j.bbrep.2022.101308. eCollection 2022 Sep.
10
Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma.表观遗传改变作为胰腺导管腺癌生物标志物和新型治疗靶点的新作用
Cancers (Basel). 2022 Jan 21;14(3):546. doi: 10.3390/cancers14030546.

本文引用的文献

1
MiR-29b/TET1/ZEB2 signaling axis regulates metastatic properties and epithelial-mesenchymal transition in breast cancer cells.微小RNA-29b/四氢叶酸双加氧酶1/锌指E盒结合蛋白2信号轴调控乳腺癌细胞的转移特性及上皮-间质转化
Oncotarget. 2017 Oct 31;8(60):102119-102133. doi: 10.18632/oncotarget.22183. eCollection 2017 Nov 24.
2
Nuclear cloning of embryonal carcinoma cells.胚胎癌细胞的核克隆
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):13985-90. doi: 10.1073/pnas.0405015101. Epub 2004 Aug 11.
3
Mouse embryos cloned from brain tumors.从脑肿瘤克隆的小鼠胚胎。
Cancer Res. 2003 Jun 1;63(11):2733-6.

原发性胰腺癌细胞的表观遗传重编程可逆转其体内致瘤性。

Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity.

机构信息

Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.

Department of Developmental Biology, University of Science and Culture, Tehran, Iran.

出版信息

Oncogene. 2019 Aug;38(34):6226-6239. doi: 10.1038/s41388-019-0871-x. Epub 2019 Jul 15.

DOI:10.1038/s41388-019-0871-x
PMID:31308488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6756074/
Abstract

Pancreatic ductal adenocarcinoma (PDAC) arises through accumulation of multiple genetic alterations. However, cancer cells also acquire and depend on cancer-specific epigenetic changes. To conclusively demonstrate the crucial relevance of the epigenetic programme for the tumourigenicity of the cancer cells, we used cellular reprogramming technology to reverse these epigenetic changes. We reprogrammed human PDAC cultures using three different techniques - (1) lentivirally via induction of Yamanaka Factors (OSKM), (2) the pluripotency-associated gene OCT4 and the microRNA mir-302, or (3) using episomal vectors as a safer alternative without genomic integration. We found that induction with episomal vectors was the most efficient method to reprogram primary human PDAC cultures as well as primary human fibroblasts that served as positive controls. Successful reprogramming was evidenced by immunostaining, alkaline phosphatase staining, and real-time PCR. Intriguingly, reprogramming of primary human PDAC cultures drastically reduced their in vivo tumourigenicity, which appeared to be driven by the cells' enhanced differentiation and loss of stemness upon transplantation. Our study demonstrates that reprogrammed primary PDAC cultures are functionally distinct from parental PDAC cells resulting in drastically reduced tumourigenicity in vitro and in vivo. Thus, epigenetic alterations account at least in part for the tumourigenicity and aggressiveness of pancreatic cancer, supporting the notion that epigenetic modulators could be a suitable approach to improve the dismal outcome of patients with pancreatic cancer.

摘要

胰腺导管腺癌 (PDAC) 是通过积累多种遗传改变而发生的。然而,癌细胞也会获得并依赖于特定的癌症表观遗传变化。为了确凿地证明表观遗传程序对癌细胞致瘤性的关键相关性,我们使用细胞重编程技术来逆转这些表观遗传变化。我们使用三种不同的技术——(1) 通过诱导 Yamanaka 因子 (OSKM) 的慢病毒,(2) 多能相关基因 OCT4 和 microRNA mir-302,或 (3) 使用无基因组整合的更安全的附加体载体,对人 PDAC 培养物进行重编程。我们发现,使用附加体载体诱导是重编程原代人 PDAC 培养物以及用作阳性对照的原代人成纤维细胞的最有效方法。成功重编程的证据是免疫染色、碱性磷酸酶染色和实时 PCR。有趣的是,重编程原代人 PDAC 培养物可大大降低其体内致瘤性,这似乎是由于细胞在移植后增强的分化和失去干性所致。我们的研究表明,重编程的原代 PDAC 培养物在功能上与亲本 PDAC 细胞明显不同,导致体外和体内致瘤性大大降低。因此,表观遗传改变至少部分解释了胰腺癌的致瘤性和侵袭性,支持了表观遗传调节剂可能是改善胰腺癌患者不良预后的一种合适方法的观点。